NO20052264L - Pregabalinderivater for behandling av fibromyalgi og andre forstyrrelser - Google Patents

Pregabalinderivater for behandling av fibromyalgi og andre forstyrrelser

Info

Publication number
NO20052264L
NO20052264L NO20052264A NO20052264A NO20052264L NO 20052264 L NO20052264 L NO 20052264L NO 20052264 A NO20052264 A NO 20052264A NO 20052264 A NO20052264 A NO 20052264A NO 20052264 L NO20052264 L NO 20052264L
Authority
NO
Norway
Prior art keywords
carbon atoms
linear
fibromyalgia
agoraphobia
disorders
Prior art date
Application number
NO20052264A
Other languages
English (en)
Norwegian (no)
Other versions
NO20052264D0 (no
Inventor
David Juergen Wustrow
Jr Charles Price Taylor
Andrew John Thorpe
David James Dooley
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32600153&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20052264(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of NO20052264D0 publication Critical patent/NO20052264D0/no
Publication of NO20052264L publication Critical patent/NO20052264L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/14—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Reproductive Health (AREA)
  • Anesthesiology (AREA)
  • Otolaryngology (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NO20052264A 2002-12-13 2005-05-10 Pregabalinderivater for behandling av fibromyalgi og andre forstyrrelser NO20052264L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US43349102P 2002-12-13 2002-12-13
US48774003P 2003-07-16 2003-07-16
PCT/IB2003/005712 WO2004054566A1 (fr) 2002-12-13 2003-12-03 Derives de pregabalin pour le traitement de la fibromyalgie et d'autres troubles

Publications (2)

Publication Number Publication Date
NO20052264D0 NO20052264D0 (no) 2005-05-10
NO20052264L true NO20052264L (no) 2005-09-12

Family

ID=32600153

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20052264A NO20052264L (no) 2002-12-13 2005-05-10 Pregabalinderivater for behandling av fibromyalgi og andre forstyrrelser

Country Status (15)

Country Link
US (1) US20090203782A1 (fr)
EP (2) EP1572188A1 (fr)
JP (1) JP2006513257A (fr)
KR (1) KR20050085636A (fr)
CN (1) CN101862317A (fr)
AU (1) AU2003303040B2 (fr)
BR (1) BR0317253A (fr)
CA (1) CA2505788A1 (fr)
MX (1) MXPA05006320A (fr)
NO (1) NO20052264L (fr)
NZ (1) NZ540591A (fr)
PL (1) PL377520A1 (fr)
RU (2) RU2353358C2 (fr)
TW (1) TW200423925A (fr)
WO (1) WO2004054566A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA05010515A (es) 2003-03-31 2006-03-10 Xenoport Inc Tratamiento o prevencion de sofocos calientes utilizando profarmacos de analogos de gaba.
KR20060087560A (ko) * 2003-09-12 2006-08-02 워너-램버트 캄파니 엘엘씨 알파-2-델타 리간드 및 ｓｓｒｉ 및/또는 ｓｎｒｉ를포함하는 우울증 및 불안 장애 치료용 조합물
US20070141684A1 (en) 2005-12-21 2007-06-21 Pfizer Inc Preparation of gamma-amino acids having affinity for the alpha-2-delta protein
US9394236B2 (en) 2014-02-03 2016-07-19 Quadriga Biosciences, Inc. β-substituted γ-amino acids and analogs as chemotherapeutic agents
WO2015117147A1 (fr) 2014-02-03 2015-08-06 Quadriga Biosciences, Inc. Acides bêta-aminés substitués en bêta et analogues en tant qu'agents de chimiothérapie
CA2994404C (fr) 2015-08-03 2020-12-08 Quadriga Biosciences, Inc. Acides beta-amines substitues en beta et analogues a utiliser en tant qu'agents de chimiotherapie et leurs utilisations
CN115739134B (zh) * 2022-11-24 2024-08-02 贵州大学 一种利用三氯化钌废弃物制备氯乙烯合成用复合催化剂的方法

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2460891C2 (de) 1974-12-21 1982-09-23 Gödecke AG, 1000 Berlin 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
US4087544A (en) 1974-12-21 1978-05-02 Warner-Lambert Company Treatment of cranial dysfunctions using novel cyclic amino acids
RU94046105A (ru) 1992-05-20 1997-06-20 Нортвестерн Юниверсити (Us) АНАЛОГИ γ -АМИНОМАСЛЯНОЙ КИСЛОТЫ И L-ГЛУТАМИНОВОЙ КИСЛОТЫ И СПОСОБЫ ИХ ПОЛУЧЕНИЯ
TW444018B (en) 1992-12-17 2001-07-01 Pfizer Pyrazolopyrimidines
CA2150703C (fr) 1992-12-17 2002-01-08 Pfizer Limited Pyrazoles substitues
US5712303A (en) 1992-12-17 1998-01-27 Pfizer Inc. Pyrazoles and pyrazolopyrimidines having CRF antagonistic activity
ES2128544T3 (es) 1992-12-17 1999-05-16 Pfizer Pirrolopirimidinas como antagonistas del crf.
TW336932B (en) 1992-12-17 1998-07-21 Pfizer Amino-substituted pyrazoles
US5670539A (en) * 1993-07-21 1997-09-23 New York State Office Of Mental Health Treatment of movement disorders using large neutral amino acids
US6372792B1 (en) * 1996-04-26 2002-04-16 Guy Chouinard Method for treating anxiety, anxiety disorders and insomnia
US6001876A (en) * 1996-07-24 1999-12-14 Warner-Lambert Company Isobutylgaba and its derivatives for the treatment of pain
SE9603408D0 (sv) * 1996-09-18 1996-09-18 Astra Ab Medical use
NZ334898A (en) 1996-10-23 2000-09-29 Warner Lambert Co Substituted gamma aminobutyric acids as pharamceutical agents
US6127418A (en) * 1997-08-20 2000-10-03 Warner-Lambert Company GABA analogs to prevent and treat gastrointestinal damage
KR100589066B1 (ko) 1997-10-27 2006-06-13 워너-램버트 캄파니 엘엘씨 약제로서 유용한 시클릭 아미노산 및 그의 유도체
US6306910B1 (en) 1998-07-09 2001-10-23 Warner-Lambert Company Use of Gaba-analogues for treating insomnia
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
WO2000061188A1 (fr) * 1999-04-09 2000-10-19 Euro-Celtique S.A. Composition de blocage du canal sodique et leur utilisation
US6642398B2 (en) * 1999-06-10 2003-11-04 Warner-Lambert Company Mono-and disubstituted 3-propyl gamma-aminobutyric acids
CA2374755C (fr) * 1999-06-10 2010-03-30 Warner-Lambert Company Acides 3-propyle gamma-aminobutyriques monosubstitues et disubstitues
US7164034B2 (en) * 1999-06-10 2007-01-16 Pfizer Inc. Alpha2delta ligands for fibromyalgia and other disorders
US6309663B1 (en) * 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
NZ517044A (en) * 1999-07-22 2004-02-27 Univ Rochester Gamma-aminobutyric acid analogues, e.g. gabapentin and pregabalin, to treat symptoms of hormonal variation, including hot flushes, nausea, emesis and fever
US6281207B1 (en) * 1999-09-15 2001-08-28 Reed Richter Treatment of movement disorders by administration of mirtazapine
HN2000000224A (es) 1999-10-20 2001-04-11 Warner Lambert Co Aminoacidos biciclicos como agentes farmaceuticos
GB2362646A (en) 2000-05-26 2001-11-28 Warner Lambert Co Cyclic amino acid derivatives useful as pharmaceutical agents
GB2365425A (en) * 2000-08-01 2002-02-20 Parke Davis & Co Ltd Alkyl amino acid derivatives useful as pharmaceutical agents
US20020099013A1 (en) * 2000-11-14 2002-07-25 Thomas Piccariello Active agent delivery systems and methods for protecting and administering active agents
IL145584A0 (en) * 2000-10-02 2002-06-30 Pfizer Prod Inc Nmda nr2b antagonists for treatment
WO2002069974A1 (fr) * 2001-03-05 2002-09-12 Andrew Holman Administration d'agents restaurateurs de sommeil
BR0209973A (pt) * 2001-05-25 2004-04-06 Warner Lambert Co Composição farmacêutica lìquida

Also Published As

Publication number Publication date
JP2006513257A (ja) 2006-04-20
NO20052264D0 (no) 2005-05-10
NZ540591A (en) 2008-03-28
TW200423925A (en) 2004-11-16
CA2505788A1 (fr) 2004-07-01
BR0317253A (pt) 2005-11-01
CN101862317A (zh) 2010-10-20
WO2004054566A1 (fr) 2004-07-01
EP1572188A1 (fr) 2005-09-14
US20090203782A1 (en) 2009-08-13
EP2172197A1 (fr) 2010-04-07
AU2003303040A1 (en) 2004-07-09
PL377520A1 (pl) 2006-02-06
RU2005118081A (ru) 2006-01-20
KR20050085636A (ko) 2005-08-29
RU2353358C2 (ru) 2009-04-27
AU2003303040B2 (en) 2009-04-23
MXPA05006320A (es) 2005-08-26
RU2008140653A (ru) 2010-04-20

Similar Documents

Publication Publication Date Title
RU2405774C2 (ru) Гетероциклические ингибиторы аспартилпротеазы
DE60325830D1 (de) Substituiertes phenylalkansäurederivat und dessen verwendung
NO20052580L (no) Blandinger for behandling av infeksjon av Flavivirida viruser
EA201070202A1 (ru) Производное оксопиразина и гербицид
DE602004003389D1 (de) Verfahren zur herstellung von 4'-azidonukleosidderivaten
CA2315262A1 (fr) Composes des cyclopentane et cyclopentene convenant comme inhibiteurs de neuraminidase
IL182866A0 (en) Process for stabilising thiophene derivatives
NZ705710A (en) Bicyclo[3.2.1]octyl amide derivatives and uses of same
BR9509212A (pt) Composto composição farmacêutica método de inibição de prostaglandina H sintase em um mamífero método de tratamento de uma doença inflamatória em um mamífero e método de tratamento de pirese em um mamífero
NO20064251L (no) Benzamidazolderivater og anvendelse derav
BR0208805A (pt) Uso de um derivado de pirazolina
NO20091858L (no) Hydrobenzamid derivater som inhibitorer av HSP90
ATE264311T1 (de) Verbindungen zur behandlung und vorsorge bei diabetes
DE60237128D1 (de) Verfahren zur Herstellung von Isopulegol
NO20010487L (no) Disubstituert maleimidforbindelse og farmasøytisk anvendelse herav
WO2004031160A3 (fr) Composes derives de la 2-thiohydantoïne et leur utilisation pour le traitement du diabete
NO20062617L (no) Anvendelse av glukosidase inhibitorer for terapi av mucovisidose
BR8202861A (pt) Composto composicao farmaceutica processo para baixar a pressao sanguinea de seres humanos processo para preparar um composto e process para preparar uma composicao farmaceutica
BR0311719A (pt) Fluorobenzamidas
EA200100640A1 (ru) Ингибиторы вирусов герпеса, представляющие собой ацетамид и замещенные ацетамидосодержащие тиомочевины
NO971687D0 (no) Diazepinoindoler som forsfodiesterase IV-inhibitorer
DE69400723D1 (de) Verwendung von Pyridoxal-Derivaten zur Herstellung eines Arzneimittels zur Behandlung des Katarakts
EP1147772A4 (fr) Compositions medicamenteuses utilisees dans le traitement de la fibrillation auriculaire
MXPA05008706A (es) 4-[(2, 4- dicloro-5 -metoxifenil) amino]-6 -alcoxi -3- quinolincarbonitrilos para tratamiento de lesiones isquemicas.
EA200100631A1 (ru) Ингибиторы вирусов герпеса, представляющие собой гетероциклические карбоксамидсодержащие тиомочевины, имеющие фенилендиаминогруппу

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application